<DOC>
	<DOCNO>NCT02229981</DOCNO>
	<brief_summary>The investigator conduct sequential Phase 1 IIa trial identify maximum tolerate dose evaluate safety , tolerability , toxicity , pharmacokinetics pharmacodynamics oral anti-cancer agent ABC294640 specifically patient diffuse large B-cell lymphoma , include patient virus-induced ( e.g. , KSHV- EBV-associated ) lymphoma .</brief_summary>
	<brief_title>An Early-Phase Clinical Trial Evaluating ABC294640 Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Pathologically confirm DLBCL radiographically refractory standard therapy , relapse follow standard therapy ( one tumor measurable PETCT scan ; see caveat antineoplastic therapy Exclusion criterion ) Tumor progression receive standard/approved chemotherapy , lack candidacy standard therapy One tumor measurable MRI PET scan Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 3 Life expectancy least 3 month Age great equal 18 year Signed , write IRBapproved informed consent A negative pregnancy test ( female ) Acceptable liver function : Bilirubin ≤ 3 time upper limit normal ( CTCAE Grade 2 baseline ) AST ( SGOT ) , ALT ( SGPT ) ≤3 x ULN ( CTCAE Grade 1 baseline ) Serum creatinine ≤ 1.5 X ULN ( CTCAE Grade 1 baseline ) Acceptable hematologic status : Absolute neutrophil count ≥ 1000 cells/mm3 Platelet ≥75,000 ( plt/mm3 ) ( CTCAE Grade 1 baseline ) Hemoglobin ≥ 8 g/dL Urinalysis : No clinically significant abnormality . PT PTT ≤ 1.5 X ULN correction nutritional deficiency may contribute prolonged PT/PTT . For men woman childproducing potential , willingness use effective contraceptive method study . If female ( female partner male subject ) , either childbearing potential ( define postmenopausal ≥ 1 year surgically sterile [ bilateral tubal ligation , bilateral oophorectomy hysterectomy ] ) practice one follow medically acceptable method birth control agree continue regimen throughout duration study : Oral , implantable injectable contraceptive 3 consecutive month Baseline/Randomization Visit . Total abstinence sexual intercourse ( ≥ 1 complete menstrual cycle Baseline/Randomization Visit ) . Intrauterine device ( IUD ) . Double barrier method ( condom , sponge , diaphragm vaginal ring spermicidal jelly cream ) . New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia , evidence ischemia ECG . Pregnant nursing woman . NOTE : Women childbearing potential men must agree use barrier method ( preferably condom ) method birth control doctor 's discretion , abstain sexual activity , prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients active , lifethreatening bacterial fungal infection Treatment radiation therapy , surgery , chemotherapy , investigational therapy within one month prior study entry Unwillingness inability comply procedure require protocol . Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , condition ) could compromise protocol objective opinion Investigator and/or Sponsor Patients currently receive investigational agent Patients receive drug highly active antiretroviral therapy ( HAART ) trimethoprimsulfamethoxazole sensitive substrate CYP450 1A2 , 3A4 , 2C9 , 2D6 , 2C19 , strong inhibitor inducer isozymes stop least 7 day 5 halflives ( whichever longer ) start treatment ABC294640 either replace another appropriate medication give duration clinical study . Patients HAART restrict preferred , potent agent demonstrate interaction CYP450 isoforms significant interaction predict ABC294640 ( 1A2 , 2C9 , 2C19 ABC294640 IC50 &lt; 1uM ) . These include tenofovir , FTC , 3TC , abacavir , darunavir , atazanavir , norvir , raltegravir , dolutegravir , elvitegravir , cobicistat , maraviroc . Switching ART prior study entry permit give significant data improvement/maintenance HIV suppression switch regimen context . Patients currently take coumadin coumadin derivative . Patients receive antineoplastic therapy within 1 month start treatment ABC294640 adequately recover side effect toxicity previous antineoplastic therapy Patients currently participate clinical trial investigational product Allergy radiographic contrast .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>B-cell Lymphomas</keyword>
	<keyword>Lymphosarcoma</keyword>
	<keyword>Kaposi 's Sarcoma-associated Herpesvirus</keyword>
	<keyword>KHSV</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>HIV</keyword>
	<keyword>Epstein-Barr Virus</keyword>
	<keyword>EBV</keyword>
</DOC>